Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$134130.0.

  • Inhibikase Therapeutics' Cash from Financing Activities fell 17371.64% to -$134130.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $99.6 million, marking a year-over-year increase of 262446.62%. This contributed to the annual value of $103.5 million for FY2024, which is 113114.37% up from last year.
  • Per Inhibikase Therapeutics' latest filing, its Cash from Financing Activities stood at -$134130.0 for Q3 2025, which was down 17371.64% from $31771.0 recorded in Q2 2025.
  • Over the past 5 years, Inhibikase Therapeutics' Cash from Financing Activities peaked at $99.7 million during Q4 2024, and registered a low of -$409662.0 during Q1 2021.
  • Over the past 5 years, Inhibikase Therapeutics' median Cash from Financing Activities value was $30831.5 (recorded in 2021), while the average stood at $10.9 million.
  • Within the past 5 years, the most significant YoY rise in Inhibikase Therapeutics' Cash from Financing Activities was 169289351.02% (2021), while the steepest drop was 26378.62% (2021).
  • Over the past 5 years, Inhibikase Therapeutics' Cash from Financing Activities (Quarter) stood at $29892.0 in 2021, then crashed by 785.03% to -$204769.0 in 2022, then surged by 32.56% to -$138104.0 in 2023, then surged by 72280.72% to $99.7 million in 2024, then tumbled by 100.13% to -$134130.0 in 2025.
  • Its Cash from Financing Activities was -$134130.0 in Q3 2025, compared to $31771.0 in Q2 2025 and $99.7 million in Q4 2024.